SEGMENT REPORTING - Revenue (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($) segment	Dec. 31, 2021 USD ($) segment	Dec. 31, 2020 USD ($)
Segment reporting
Number of segments | segment	2	1
Revenue recognition	$ 316,385	$ 216,136	$ 208,475
Depreciation and amortization	56,972	47,252	44,638
Corporate and other unallocated expenses	124,044	84,294	64,986
Operating Loss	(35,283)	(39,793)	(16,016)
Interest expense, net	(28,052)	(11,922)	(9,452)
Other income/(expense), net	670	(4,343)	(494)
Loss Before Benefit for Income Taxes	(62,665)	(56,058)	(25,962)
Operating segments | Generics, Established Brands and Other
Segment reporting
Revenue recognition	274,698	216,136	208,475
EBITDA	78,958	63,418	78,790
Operating segments | Rare Disease
Segment reporting
Revenue recognition	41,687
EBITDA	(18,348)	(18,571)	(15,620)
Unallocated expenses
Segment reporting
Depreciation and amortization	(56,973)	(47,252)	(44,638)
Corporate and other unallocated expenses	(38,920)	(37,388)	(34,548)
Operating Loss	(35,283)	(39,793)	(16,016)
Interest expense, net	(28,052)	(11,922)	(9,452)
Other income/(expense), net	$ 670	$ (4,343)	$ (494)